FDA Clears Ranibizumab for Myopic Choroidal Neovascularization FDA Clears Ranibizumab for Myopic Choroidal Neovascularization

Ranibizumab becomes the first FDA-approved anti-vascular endothelial growth factor therapy for mCNV.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news